Feb 15, 2024, 18:29
The MARGOT is optimizing preoperative therapy for Stage II-III HER2+ breast cancer – Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X/Twitter:
”The MARGOT study led by Dana-Farber’s Breast Oncology Center and Translational Breast Cancer Research Consortium is optimizing preoperative therapy for Stage II-III HER2+ breast cancer, comparing paclitaxel/margetuximab/pertuzumab to paclitaxel/trastuzumab/pertuzumab. For more information call 877-338-7425 or visit the website.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 23:10
Nov 12, 2024, 23:07
Nov 12, 2024, 22:58
Nov 12, 2024, 22:56
Nov 12, 2024, 22:50
Nov 12, 2024, 22:46
Nov 12, 2024, 22:43